Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6655119 | 0.91 | CYP11B2 (0.51) | CYP11B2CYP11B1HTR6CYP19A1CYP17A1 | |
| SCHEMBL6846125 | 0.90 | CYP11B2 (0.59) | CYP11B2CYP11B1CYP19A1CYP17A1MAPT | |
| SCHEMBL22515748 | 0.89 | CYP11B2 (0.49) | CYP11B2CYP11B1HTR6CYP19A1CYP17A1 | |
| SCHEMBL6662535 | 0.89 | CYP19A1 (0.51) | CYP11B2CYP11B1CYP19A1CYP17A1MAPT | |
| SCHEMBL16538914 | 0.89 | CYP11B2 (0.49) | CYP11B2CYP11B1HTR6CYP19A1CYP17A1 | |
| SCHEMBL6656090 | 0.89 | CYP11B2 (0.50) | CYP11B2CYP11B1CYP19A1CYP17A1MAPT | |
| SCHEMBL6663687 | 0.89 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP19A1CYP17A1CYP3A4 | |
| SCHEMBL6844272 | 0.88 | HTR6 (0.50) | CYP11B2CYP11B1HTR6CYP19A1CYP17A1 | |
| SCHEMBL6847487 | 0.88 | CYP11B2 (0.43) | CYP11B2CYP11B1HTR6CYP3A4 | |
| SCHEMBL22515743 | 0.86 | CYP11B2 (0.53) | CYP11B2CYP11B1HTR6CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP11B2 53/4885CYP11B1 30/4885HTR6 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.